Phase I trial of α-particle therapy with actinium-225 (225Ac)-lintuzumab (anti-CD33) and low-dose cytarabine (LDAC) in older patients with untreated acute myeloid leukemia (AML.
7050 Background: 225Ac-lintuzumab consists of a radiometal that emits 4 α-particles linked to an anti-CD33 antibody. A phase I trial showed safety and efficacy of 225Ac-lintuzumab in relapsed AML. We are conducting a multicenter, phase I trial to determine the maximum tolerated dose (MTD), toxicity, and activity of fractionated-dose 225Ac-lintuzumab combined with LDAC. Methods: Patients ≥ 60 yrs with untreated AML not suitable for standard induction were eligible. Patients received LDAC 20 mg BID for 10 d every 4-6 wks for up to 12 cycles. During Cycle 1, 2 doses of 225Ac-lintuzumab were given one week apart, 4-7 d following LDAC. 225Ac doses were escalated using a 3+3 design. Results: Twelve patients (median age, 77 yrs; range, 68-87 yrs) were treated. Eight (67%) had prior myelodysplastic syndrome, for which 6 (75%) received hypomethylating agents (n = 5) or allogeneic stem cell transplant (n = 1). One (8%) had chronic myeloid leukemia in molecular remission prior to AML. Nine patients (75%) had interme...